"CD40 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
| Descriptor ID |
D023201
|
| MeSH Number(s) |
D12.644.276.374.750.124 D12.776.395.550.185 D12.776.467.374.750.124 D12.776.543.550.198 D23.529.374.750.124
|
| Concept/Terms |
CD40 Ligand- CD40 Ligand
- gp39 Antigen, T-Cell
- T-Cell gp39 Antigen
- gp39 Antigen, T Cell
- CD40L
- Tumor Necrosis Factor Ligand Superfamily Member 5
- Antigen, CD154
- CD154 Antigen
- T-B Cell Activating Molecule
- TNF Superfamily, Member 5
- CD154 Antigens
- Antigens, CD154
|
Below are MeSH descriptors whose meaning is more general than "CD40 Ligand".
Below are MeSH descriptors whose meaning is more specific than "CD40 Ligand".
This graph shows the total number of publications written about "CD40 Ligand" by people in this website by year, and whether "CD40 Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 3 | 5 |
| 2002 | 4 | 1 | 5 |
| 2003 | 2 | 3 | 5 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD40 Ligand" by people in Profiles.
-
CAR Treg synergy with anti-CD154 promotes infectious tolerance and dictates allogeneic heart transplant acceptance. JCI Insight. 2025 Apr 08; 10(7).
-
Methods to Study TLRs in Transplantation. Methods Mol Biol. 2023; 2700:139-149.
-
Downregulation of CD40L-CD40 attenuates seizure susceptibility and severity of seizures. Sci Rep. 2021 08 26; 11(1):17262.
-
Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:1076029620943300.
-
Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation. Clin Appl Thromb Hemost. 2018 Jul; 24(5):803-807.
-
Comparative Evaluation of aCD40 (2C10R4) and aCD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. Transplantation. 2017 09; 101(9):2038-2047.
-
PKC-epsilon and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages. Atherosclerosis. 2017 04; 259:51-59.
-
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013 Nov; 1(5):340-50.
-
Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am J Transplant. 2013 Sep; 13(9):2280-92.
-
Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade. Clin Dev Immunol. 2013; 2013:986859.